Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22, 2024 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
Dec 3, 2024 · Methodology. For this database, BioPharma Dive includes biotech companies that raised funds in an initial public offering on a U.S. stock exchange.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Paragon spinout joins hunt for new type of cancer immunotherapy
Oct 29, 2024 · On a conference call Tuesday, Crescent CEO Violin said CR-001 was specially made to be an optimized version of ivonescimab, the Akeso and Summit Therapeutics drug that bested Keytruda in a Phase 3 trial in lung cancer.
5 FDA decisions to watch in the fourth quarter | BioPharma Dive
Oct 1, 2024 · 5 FDA decisions to watch in the fourth quarter Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex’s dominant cystic fibrosis business.